

## ABSTRACT

**SELECTIVE INHIBITOR OF EXON 18 AND/OR EXON 21 MUTANT EGFR**

An antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected  
5 from the group consisting of G719X mutation of exon 18, E709X mutation of exon 18, and L861X mutation of exon 21, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising  
10 (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof.

[FIG.1]